RetaCalc
Protocol library
SingleApprovedRegulatory LabelSourced

Tirzepatide

A GIP and GLP-1 receptor agonist with authorised prescription products. Label regimens apply only to regulated medicines under clinical care.

Evidence context, not a personal protocol

Quantities below reproduce study or label context. They do not assess suitability, product equivalence or individual risk.

Regimens studied

Adults meeting the authorised Zepbound indication

The label starts at 2.5 mg once weekly and uses 2.5 mg escalation steps after at least 4 weeks at the current dose

This is a summary of a US prescription label and is not a recommendation for a research product.

View source

Evidence summary

Tirzepatide has regulated prescription formulations for specific indications. Regulatory status does not transfer to unlicensed or research-labelled material.

Label context

The current product label is the controlling source for indications, dosage forms, warnings, interactions, pregnancy information and storage. A prescriber must determine whether it is appropriate for an individual.

Warnings and contraindications

Authorised labels contain boxed warnings, contraindications and medicine-specific handling instructions.
Research vials are not interchangeable with regulated pre-filled prescription products.

Contraindications reported by the source

Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2